Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

NCT00382798 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Hepatitis C Virus

Interventions

DRUG: RO5024048

Sponsor

Pharmasset

Collaborators

[object Object]